AstraZeneca blood pressure drug succeeds in late-stage trial

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose hypertension is either uncontrolled by or resistant to existing medicines.

Related posts

Pfizer launches cost savings program on TrumpRx lowering drug costs for millions of Americans

February 23, 2026

Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study

February 23, 2026

Source link